88 related articles for article (PubMed ID: 10613369)
1. Quinupristin and dalfopristin.
Am J Health Syst Pharm; 1999 Dec; 56(24):2530-1. PubMed ID: 10613369
[No Abstract] [Full Text] [Related]
2. Anemia and reversible reticulocytopenia associated with extended quinupristin/dalfopristin.
Evans PC; Almas JP; Criddle FJ
Ann Pharmacother; 2004 Apr; 38(4):720-1. PubMed ID: 14766992
[No Abstract] [Full Text] [Related]
3. Linezolid, quinupristin/dalfopristin, and daptomycin in dermatology.
Wesson KM; Lerner DS; Silverberg NB; Weinberg JM
Clin Dermatol; 2003; 21(1):64-70. PubMed ID: 12609590
[No Abstract] [Full Text] [Related]
4. Quinupristin-dalfopristin-induced reticulocytopenic anemia.
Chan-Tack KM; Mehta S
South Med J; 2005 Dec; 98(12):1226-7. PubMed ID: 16440929
[No Abstract] [Full Text] [Related]
5. Linezolid, quinupristin/dalfopristin, and daptomycin in dermatology.
Wesson KM; Lerner DS; Silverberg NB; Weinberg JM
Dis Mon; 2004 Jul; 50(7):395-406. PubMed ID: 15280870
[No Abstract] [Full Text] [Related]
6. Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.
Lamb HM; Figgitt DP; Faulds D
Drugs; 1999 Dec; 58(6):1061-97. PubMed ID: 10651391
[TBL] [Abstract][Full Text] [Related]
7. Severe reversible reticulocytopenic anemia associated with quinupristin/dalfopristin RP59500 therapy.
Launay O; Chemlal K; Andrieu V; Carbon C
Clin Infect Dis; 1997 Jul; 25(1):156. PubMed ID: 9243054
[No Abstract] [Full Text] [Related]
8. Safety and tolerability of quinupristin/dalfopristin: administration guidelines.
Rubinstein E; Prokocimer P; Talbot GH
J Antimicrob Chemother; 1999 Sep; 44 Suppl A():37-46. PubMed ID: 10511396
[TBL] [Abstract][Full Text] [Related]
9. Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group.
Fagon J; Patrick H; Haas DW; Torres A; Gibert C; Cheadle WG; Falcone RE; Anholm JD; Paganin F; Fabian TC; Lilienthal F
Am J Respir Crit Care Med; 2000 Mar; 161(3 Pt 1):753-62. PubMed ID: 10712318
[TBL] [Abstract][Full Text] [Related]
10. Treatment of vancomycin-resistant Enterococcus faecium infections with an investigational streptogramin antibiotic (quinupristin/dalfopristin): a report of fifteen cases.
Dever LL; Smith SM; Dejesus D; Masurekar M; Patel D; Kaminski ZC; Johanson WG
Microb Drug Resist; 1996; 2(4):407-13. PubMed ID: 9158811
[TBL] [Abstract][Full Text] [Related]
11. Treatment of vancomycin-resistant Enterococcus faecium infections with quinupristin/dalfopristin.
Linden PK; Moellering RC; Wood CA; Rehm SJ; Flaherty J; Bompart F; Talbot GH;
Clin Infect Dis; 2001 Dec; 33(11):1816-23. PubMed ID: 11668430
[TBL] [Abstract][Full Text] [Related]
12. Quinupristin-dalfopristin versus linezolid for the treatment of vancomycin-resistant Enterococcus faecium bacteraemia: efficacy and development of resistance.
Chong YP; Lee SO; Song EH; Lee EJ; Jang EY; Kim SH; Choi SH; Kim MN; Jeong JY; Woo JH; Kim YS
Scand J Infect Dis; 2010 Jul; 42(6-7):491-9. PubMed ID: 20524781
[TBL] [Abstract][Full Text] [Related]
13. Quinupristin/dalfopristin in vancomycin-resistant Staphylococcus aureus endophthalmitis.
Stroh EM
Arch Ophthalmol; 2012 Oct; 130(10):1323-4. PubMed ID: 23044949
[No Abstract] [Full Text] [Related]
14. Clinical experience with quinupristin-dalfopristin as rescue treatment of critically ill patients infected with methicillin-resistant staphylococci.
Sander A; Beiderlinden M; Schmid EN; Peters J
Intensive Care Med; 2002 Aug; 28(8):1157-60. PubMed ID: 12185441
[TBL] [Abstract][Full Text] [Related]
15. Interaction between quinupristin/dalfopristin and cyclosporine.
Stamatakis MK; Richards JG
Ann Pharmacother; 1997 May; 31(5):576-8. PubMed ID: 9161651
[TBL] [Abstract][Full Text] [Related]
16. Quinupristin/dalfopristin and linezolid: spectrum of activity and potential roles in therapy--a status report.
Batts DH; Lavin BS; Eliopoulos GM
Curr Clin Top Infect Dis; 2001; 21():227-51. PubMed ID: 11572153
[No Abstract] [Full Text] [Related]
17. Treatment of vancomycin-resistant enterococcus with quinupristin/dalfopristin and high-dose ampicillin.
Bethea JA; Walko CM; Targos PA
Ann Pharmacother; 2004 Jun; 38(6):989-91. PubMed ID: 15100393
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo effects of quinupristin-dalfopristin against Pneumocystis carinii.
Walzer PD; Ashbaugh A; Collins M; Cushion MT
Antimicrob Agents Chemother; 2001 Nov; 45(11):3234-7. PubMed ID: 11600389
[TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacokinetics of quinupristin/dalfopristin.
Bearden DT
Clin Pharmacokinet; 2004; 43(4):239-52. PubMed ID: 15005638
[TBL] [Abstract][Full Text] [Related]
20. [symbol: see text]Quinupristin + dalfopristin for infections.
Drug Ther Bull; 2002 Feb; 40(2):15-6. PubMed ID: 11892373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
